Back to top

immuno-therapy: Archive

Zacks Equity Research

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on Avalo Therapeutics' (AVTX) lead pipeline drug when it reports fourth-quarter earnings results.

SRPTNegative Net Change ARQTPositive Net Change CGEMPositive Net Change AVTXNegative Net Change